#COYA
Coya Therapeutics advances its Phase 2 ALS program with Health Canada CTA acceptance for COYA 302, enabling patient enrollment in Canada and expanding the ongoing ALSTARS trial alongside U.S. sites.
#CoyaTherapeutics
prismmarketview.com/coya-therape...
#COYA
#CoyaTherapeutics, Inc. announced its Phase 2 COYA 302 ALS trial has been accepted as a NEALS-Affiliated Trial. Following recent FDA IND clearance, the study is expected to begin in Q4 2025 and will be presented during a NEALS webinar later this month.
prismmarketview.com/coya-therape...
(NASDAQ: #COYA)
#CoyaTherapeutics announced FDA acceptance of its IND for COYA 302 in ALS, clearing the way for a Phase 2 trial. The milestone also triggers a $4.2M payment from partner Dr. Reddy’s, reinforcing the strategic path forward in neurodegeneration.
prismmarketview.com/coya-therape...
In recognition of ALS Awareness Month, we highlight the important work of Coya Therapeutics #COYA
#CoyaTherapeutics
